Xenical Rx-To-OTC Switch Plans Underway
GlaxoSmithKline pays Roche $100 mil. for OTC marketing rights for the anti-obesity treatment. The two companies say they "have already begun work to develop an OTC orlistat formulation in the U.S."
GlaxoSmithKline pays Roche $100 mil. for OTC marketing rights for the anti-obesity treatment. The two companies say they "have already begun work to develop an OTC orlistat formulation in the U.S."